APO Research
Talk to an analyst

APO RESEARCH · REPORT

T Cell Surface Glycoprotein CD3 Epsilon

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global T Cell Surface Glycoprotein CD3 Epsilon Market Analysis and Forecast 2026-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchT Cell Surface Glycoprotein CD3 Epsilon Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal T Cell Surface Glycoprotein CD3 Epsilon Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal T Cell Surface Glycoprotein CD3 Epsilon Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T Cell Surface Glycoprotein CD3 Epsilon Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal T Cell Surface Glycoprotein CD3 Epsilon Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global T Cell Surface Glycoprotein CD3 Epsilon market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for T Cell Surface Glycoprotein CD3 Epsilon is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for T Cell Surface Glycoprotein CD3 Epsilon is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for T Cell Surface Glycoprotein CD3 Epsilon is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for T Cell Surface Glycoprotein CD3 Epsilon is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of T Cell Surface Glycoprotein CD3 Epsilon include GlaxoSmithKline Plc, Amgen Inc, Tiziana Life Sciences Plc, SYNIMMUNE GmbH, Numab Innovation AG, Meridigen Biotech Co Ltd, MacroGenics Inc, F. Hoffmann-La Roche Ltd and Celgene Corp, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for T Cell Surface Glycoprotein CD3 Epsilon, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of T Cell Surface Glycoprotein CD3 Epsilon, also provides the revenue of main regions and countries. Of the upcoming market potential for T Cell Surface Glycoprotein CD3 Epsilon, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the T Cell Surface Glycoprotein CD3 Epsilon revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global T Cell Surface Glycoprotein CD3 Epsilon market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for T Cell Surface Glycoprotein CD3 Epsilon revenue, projected growth trends, production technology, application and end-user industry.

T Cell Surface Glycoprotein CD3 Epsilon Segment by Company

GlaxoSmithKline Plc

Amgen Inc

Tiziana Life Sciences Plc

SYNIMMUNE GmbH

Numab Innovation AG

Meridigen Biotech Co Ltd

MacroGenics Inc

F. Hoffmann-La Roche Ltd

Celgene Corp

T Cell Surface Glycoprotein CD3 Epsilon Segment by Type

ND-007

Foralumab

Coltelizumab

AVA-002

Others

T Cell Surface Glycoprotein CD3 Epsilon Segment by Application

Autoimmune Disorders

Hepatitis B

Prostate Cancer

Multiple Sclerosis

Others

T Cell Surface Glycoprotein CD3 Epsilon Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Surface Glycoprotein CD3 Epsilon market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T Cell Surface Glycoprotein CD3 Epsilon and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Surface Glycoprotein CD3 Epsilon.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of T Cell Surface Glycoprotein CD3 Epsilon in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of T Cell Surface Glycoprotein CD3 Epsilon company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, T Cell Surface Glycoprotein CD3 Epsilon revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. ND-007 Major Player Table 3. Foralumab Major Player Table 4. Coltelizumab Major Player Table 5. AVA-002 Major Player Table 6. Others Major Player Table 7. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Autoimmune Disorders Major Player Table 9. Hepatitis B Major Player Table 10. Prostate Cancer Major Player Table 11. Multiple Sclerosis Major Player Table 12. Others Major Player Table 13. T Cell Surface Glycoprotein CD3 Epsilon Industry Trends Table 14. T Cell Surface Glycoprotein CD3 Epsilon Industry Drivers Table 15. T Cell Surface Glycoprotein CD3 Epsilon Industry Opportunities and Challenges Table 16. T Cell Surface Glycoprotein CD3 Epsilon Industry Restraints Table 17. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Region (2021-2026) & (US$ Million) Table 19. Global T Cell Surface Glycoprotein CD3 Epsilon Market Share by Region (2021-2026) Table 20. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Region (2027-2032) & (US$ Million) Table 21. Global T Cell Surface Glycoprotein CD3 Epsilon Market Share by Region (2027-2032) Table 22. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Players (US$ Million) & (2021-2026) Table 23. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Players (2021-2026) Table 24. Global T Cell Surface Glycoprotein CD3 Epsilon Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global T Cell Surface Glycoprotein CD3 Epsilon Key Players Headquarters & Area Served Table 26. Global T Cell Surface Glycoprotein CD3 Epsilon Players, Product Type & Application Table 27. Global T Cell Surface Glycoprotein CD3 Epsilon Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global T Cell Surface Glycoprotein CD3 Epsilon by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026) & (US$ Million) Table 32. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032) & (US$ Million) Table 33. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Type (2021-2026) Table 34. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Type (2027-2032) Table 35. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026) & (US$ Million) Table 37. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032) & (US$ Million) Table 38. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Application (2021-2026) Table 39. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Application (2027-2032) Table 40. GlaxoSmithKline Plc Company Information Table 41. GlaxoSmithKline Plc Business Overview Table 42. GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 44. GlaxoSmithKline Plc Recent Development Table 45. Amgen Inc Company Information Table 46. Amgen Inc Business Overview Table 47. Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 49. Amgen Inc Recent Development Table 50. Tiziana Life Sciences Plc Company Information Table 51. Tiziana Life Sciences Plc Business Overview Table 52. Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 54. Tiziana Life Sciences Plc Recent Development Table 55. SYNIMMUNE GmbH Company Information Table 56. SYNIMMUNE GmbH Business Overview Table 57. SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 59. SYNIMMUNE GmbH Recent Development Table 60. Numab Innovation AG Company Information Table 61. Numab Innovation AG Business Overview Table 62. Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 64. Numab Innovation AG Recent Development Table 65. Meridigen Biotech Co Ltd Company Information Table 66. Meridigen Biotech Co Ltd Business Overview Table 67. Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 69. Meridigen Biotech Co Ltd Recent Development Table 70. MacroGenics Inc Company Information Table 71. MacroGenics Inc Business Overview Table 72. MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 74. MacroGenics Inc Recent Development Table 75. F. Hoffmann-La Roche Ltd Company Information Table 76. F. Hoffmann-La Roche Ltd Business Overview Table 77. F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 79. F. Hoffmann-La Roche Ltd Recent Development Table 80. Celgene Corp Company Information Table 81. Celgene Corp Business Overview Table 82. Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 84. Celgene Corp Recent Development Table 85. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026) & (US$ Million) Table 86. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032) & (US$ Million) Table 87. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026) & (US$ Million) Table 88. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032) & (US$ Million) Table 89. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021-2026) & (US$ Million) Table 91. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (US$ Million) & (2027-2032) Table 99. China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026) & (US$ Million) Table 100. China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032) & (US$ Million) Table 101. China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026) & (US$ Million) Table 102. China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. T Cell Surface Glycoprotein CD3 Epsilon Image Figure 2. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size Share 2021 VS 2025 VS 2032 Figure 4. ND-007 Image Figure 5. Foralumab Image Figure 6. Coltelizumab Image Figure 7. AVA-002 Image Figure 8. Others Image Figure 9. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size Share 2021 VS 2025 VS 2032 Figure 11. Autoimmune Disorders Image Figure 12. Hepatitis B Image Figure 13. Prostate Cancer Image Figure 14. Multiple Sclerosis Image Figure 15. Others Image Figure 16. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size (US$ Million) & (2021-2032) Figure 17. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global T Cell Surface Glycoprotein CD3 Epsilon Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global T Cell Surface Glycoprotein CD3 Epsilon Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Type (2021-2032) Figure 24. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Application (2021-2032) Figure 27. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032) Figure 29. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032) Figure 30. North America T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Country (2021-2032) Figure 31. United States T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032) Figure 36. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032) Figure 37. Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Country (2021-2032) Figure 38. Germany T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032) Figure 48. China T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032) Figure 49. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032) Figure 51. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032) Figure 52. Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Region (2021-2032) Figure 53. Japan T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032) Figure 61. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032) Figure 62. SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Country (2021-2032) Figure 63. Brazil T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt T Cell Surface Glycoprotein CD3 Epsilon Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • ND-007
  • Foralumab
  • Coltelizumab
  • AVA-002
  • Others
Applications
  • Autoimmune Disorders
  • Hepatitis B
  • Prostate Cancer
  • Multiple Sclerosis
  • Others
Companies covered
  • GlaxoSmithKline Plc
  • Amgen Inc
  • Tiziana Life Sciences Plc
  • SYNIMMUNE GmbH
  • Numab Innovation AG
  • Meridigen Biotech Co Ltd
  • MacroGenics Inc
  • F. Hoffmann-La Roche Ltd
  • Celgene Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 T Cell Surface Glycoprotein CD3 Epsilon Market by Type
  3. 1.2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 ND-007
  5. 1.2.3 Foralumab
  6. 1.2.4 Coltelizumab
  7. 1.2.5 AVA-002
  8. 1.2.6 Others
  9. 1.3 T Cell Surface Glycoprotein CD3 Epsilon Market by Application
  10. 1.3.1 Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Autoimmune Disorders
  12. 1.3.3 Hepatitis B
  13. 1.3.4 Prostate Cancer
  14. 1.3.5 Multiple Sclerosis
  15. 1.3.6 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 T Cell Surface Glycoprotein CD3 Epsilon Market Dynamics
  1. 2.1 T Cell Surface Glycoprotein CD3 Epsilon Industry Trends
  2. 2.2 T Cell Surface Glycoprotein CD3 Epsilon Industry Drivers
  3. 2.3 T Cell Surface Glycoprotein CD3 Epsilon Industry Opportunities and Challenges
  4. 2.4 T Cell Surface Glycoprotein CD3 Epsilon Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global T Cell Surface Glycoprotein CD3 Epsilon Market Perspective (2021-2032)
  2. 3.2 Global T Cell Surface Glycoprotein CD3 Epsilon Growth Trends by Region
  3. 3.2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Region (2021-2026)
  5. 3.2.3 Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Players
  2. 4.1.1 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Players (2021-2026)
  3. 4.1.2 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global T Cell Surface Glycoprotein CD3 Epsilon Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global T Cell Surface Glycoprotein CD3 Epsilon Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global T Cell Surface Glycoprotein CD3 Epsilon Key Players Headquarters & Area Served
  7. 4.4 Global T Cell Surface Glycoprotein CD3 Epsilon Players, Product Type & Application
  8. 4.5 Global T Cell Surface Glycoprotein CD3 Epsilon Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global T Cell Surface Glycoprotein CD3 Epsilon Market CR5 and HHI
  11. 4.6.3 2025 T Cell Surface Glycoprotein CD3 Epsilon Tier 1, Tier 2, and Tier 3
5 T Cell Surface Glycoprotein CD3 Epsilon Market Size by Type
  1. 5.1 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2032)
  3. 5.3 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Type (2021-2032)
6 T Cell Surface Glycoprotein CD3 Epsilon Market Size by Application
  1. 6.1 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2032)
  3. 6.3 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GlaxoSmithKline Plc
  2. 7.1.1 GlaxoSmithKline Plc Company Information
  3. 7.1.2 GlaxoSmithKline Plc Business Overview
  4. 7.1.3 GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  6. 7.1.5 GlaxoSmithKline Plc Recent Developments
  7. 7.2 Amgen Inc
  8. 7.2.1 Amgen Inc Company Information
  9. 7.2.2 Amgen Inc Business Overview
  10. 7.2.3 Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  12. 7.2.5 Amgen Inc Recent Developments
  13. 7.3 Tiziana Life Sciences Plc
  14. 7.3.1 Tiziana Life Sciences Plc Company Information
  15. 7.3.2 Tiziana Life Sciences Plc Business Overview
  16. 7.3.3 Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  18. 7.3.5 Tiziana Life Sciences Plc Recent Developments
  19. 7.4 SYNIMMUNE GmbH
  20. 7.4.1 SYNIMMUNE GmbH Company Information
  21. 7.4.2 SYNIMMUNE GmbH Business Overview
  22. 7.4.3 SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  23. 7.4.4 SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  24. 7.4.5 SYNIMMUNE GmbH Recent Developments
  25. 7.5 Numab Innovation AG
  26. 7.5.1 Numab Innovation AG Company Information
  27. 7.5.2 Numab Innovation AG Business Overview
  28. 7.5.3 Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  30. 7.5.5 Numab Innovation AG Recent Developments
  31. 7.6 Meridigen Biotech Co Ltd
  32. 7.6.1 Meridigen Biotech Co Ltd Company Information
  33. 7.6.2 Meridigen Biotech Co Ltd Business Overview
  34. 7.6.3 Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  36. 7.6.5 Meridigen Biotech Co Ltd Recent Developments
  37. 7.7 MacroGenics Inc
  38. 7.7.1 MacroGenics Inc Company Information
  39. 7.7.2 MacroGenics Inc Business Overview
  40. 7.7.3 MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  41. 7.7.4 MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  42. 7.7.5 MacroGenics Inc Recent Developments
  43. 7.8 F. Hoffmann-La Roche Ltd
  44. 7.8.1 F. Hoffmann-La Roche Ltd Company Information
  45. 7.8.2 F. Hoffmann-La Roche Ltd Business Overview
  46. 7.8.3 F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  47. 7.8.4 F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  48. 7.8.5 F. Hoffmann-La Roche Ltd Recent Developments
  49. 7.9 Celgene Corp
  50. 7.9.1 Celgene Corp Company Information
  51. 7.9.2 Celgene Corp Business Overview
  52. 7.9.3 Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  54. 7.9.5 Celgene Corp Recent Developments
8 North America
  1. 8.1 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue (2021-2032)
  2. 8.2 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2032)
  3. 8.2.1 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026)
  4. 8.2.2 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032)
  5. 8.3 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032)
  6. 8.4 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2032)
  7. 8.4.1 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026)
  8. 8.4.2 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032)
  9. 8.5 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032)
  10. 8.6 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country
  11. 8.6.1 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021-2026)
  13. 8.6.3 North America T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue (2021-2032)
  2. 9.2 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2032)
  3. 9.2.1 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026)
  4. 9.2.2 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032)
  5. 9.3 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032)
  6. 9.4 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2032)
  7. 9.4.1 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026)
  8. 9.4.2 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032)
  9. 9.5 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032)
  10. 9.6 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country
  11. 9.6.1 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021-2026)
  13. 9.6.3 Europe T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China T Cell Surface Glycoprotein CD3 Epsilon Revenue (2021-2032)
  2. 10.2 China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2032)
  3. 10.2.1 China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026)
  4. 10.2.2 China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032)
  5. 10.3 China T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032)
  6. 10.4 China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2032)
  7. 10.4.1 China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026)
  8. 10.4.2 China T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032)
  9. 10.5 China T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue (2021-2032)
  2. 11.2 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2032)
  3. 11.2.1 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026)
  4. 11.2.2 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032)
  5. 11.3 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032)
  6. 11.4 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2032)
  7. 11.4.1 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026)
  8. 11.4.2 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032)
  9. 11.5 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032)
  10. 11.6 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country
  11. 11.6.1 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021-2026)
  13. 11.6.3 Asia T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue (2021-2032)
  2. 12.2 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Type (2027-2032)
  5. 12.3 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Application (2027-2032)
  9. 12.5 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country
  11. 12.6.1 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA T Cell Surface Glycoprotein CD3 Epsilon Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst